An announcement from Tandem Diabetes Care ( ($TNDM) ) is now available. On December 26, 2025, Tandem Diabetes Care’s board of directors approved ...

Clinical Ink announced that it entered into a collaboration with Tandem Diabetes Care to integrate (AID) data.

Tandem Diabetes Care's top-line growth hasn't been great over the past few years. If it can successfully address challenges detrimental to revenue growth, it may become an attractive stock -- even ...

Tandem Diabetes Care, Inc.’s TNDM impressive international expansion is expected to bolster growth in the upcoming quarters. The company’s impressive strategic initiatives provide a favorable ...

Tandem Diabetes Care, an insulin delivery and diabetes technology company, announced it received FDA clearance for the Android version of its mobile app Tandem Mobi. The system, powered by Control-IQ ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full ...

During the last three months, 13 analysts shared their evaluations of Tandem Diabetes Care (NASDAQ:TNDM), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Tandem Diabetes Care Announces Publication Showing Adults With Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels This sub-analysis is the first study to evaluate ...

The U.S. Food & Drug Administration has issued an urgent medical device correction. Specifically, an error on the t:slim X2 insulin pump has been stopping insulin ...